---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-069896"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2023-06-09T23:59:59+00:00"
generated_at: "2026-06-14T03:30:50.704390+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics announces 2023 annual meeting voting results; all director nominees elected

## Summary
- Five director nominees elected with votes for ranging from 2,473,599 to 2,500,415; broker non-votes 3,193,097.
- Advisory approval of named executive officer compensation: 2,347,263 for, 321,791 against, 27,721 abstained.
- Preferred frequency of say-on-pay set to one year after 2,535,976 votes for one year.
- Ratification of Marcum LLP as auditor: 5,760,786 for, 109,958 against, 19,128 abstained.
- Total shares outstanding 8,798,829; 66.94% present at meeting.

## SEC filing metadata
- accession: 0001104659-23-069896
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2023-06-09T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465923069896/0001104659-23-069896-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465923069896/tm2317378d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-069896
- JSON: https://secwatch.observer/filing/0001104659-23-069896.json
- Plain text: https://secwatch.observer/filing/0001104659-23-069896.txt

## Key facts
- Shareholder Votes
  Marker Therapeutics, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers. at the 2023-06-06 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: Proposal No. 2 : Approval, on an advisory basis, of the compensation of the Company’s named executive officers. The votes were cast as follows: Votes For Votes Against Abstained Advisory approval of named executive officer compensation 2,347,263 321,791 27,721 Broker Non-Votes: 3,193,097.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465923069896/0001104659-23-069896-index.htm
- Shareholder Votes
  Marker Therapeutics, Inc. shareholders approved Indication, on an advisory basis, of the preferred frequency of future shareholder advisory votes on the compensation of the Company’s named executive officers. at the 2023-06-06 meeting.
  - Proposal: say on pay frequency
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: Proposal No. 3 : Indication, on an advisory basis, of the preferred frequency of future shareholder advisory votes on the compensation of the Company’s named executive officers. The votes were cast as follows: One Year Two Years Three Years Abstained Advisory indication of preferred frequency of future shareholder advisory votes on named executive officer compensation 2,535,976 25,098 102,082 33,619 Broker Non-Votes: 3,193,097.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465923069896/0001104659-23-069896-index.htm
- Shareholder Votes
  Marker Therapeutics, Inc. shareholders approved Election of five nominees to serve as directors until the 2023 annual meeting of stockholders and until their respective successors are elected and qualified. at the 2023-06-06 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: Proposal No. 1 : Election of five nominees to serve as directors until the 2023 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld David Eansor 2,488,644 208,131 Steven Elms 2,500,415 196,360 John Wilson 2,473,599 223,176 Juan Vera 2,499,068 197,707 Katharine Knobil 2,495,539 201,236 Broker Non-Votes: 3,193,097.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465923069896/0001104659-23-069896-index.htm
- Shareholder Votes
  Marker Therapeutics, Inc. shareholders approved Ratification of the selection of Marcum LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-06 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: Proposal No. 4 : Ratification of the selection of Marcum LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of Marcum LLP 5,760,786 109,958 19,128 Broker Non-Votes: 0.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465923069896/0001104659-23-069896-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.